PMID- 25520567
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141218
LR  - 20240510
IS  - 1179-5549 (Print)
IS  - 1179-5549 (Electronic)
IS  - 1179-5549 (Linking)
VI  - 8
DP  - 2014
TI  - Cancer-associated thrombosis: an overview.
PG  - 129-37
LID - 10.4137/CMO.S18991 [doi]
AB  - Venous thromboembolism (VTE) is a common complication in patients with malignant 
      disease. Emerging data have enhanced our understanding of cancer-associated 
      thrombosis, a major cause of morbidity and mortality in patients with cancer. In 
      addition to VTE, arterial occlusion with stroke and anginal symptoms is 
      relatively common among cancer patients, and is possibly related to genetic 
      predisposition. Several risk factors for developing venous thrombosis usually 
      coexist in cancer patients including surgery, hospital admissions and 
      immobilization, the presence of an indwelling central catheter, chemotherapy, use 
      of erythropoiesis-stimulating agents (ESAs) and new molecular-targeted therapies 
      such as antiangiogenic agents. Effective prophylaxis and treatment of VTE reduced 
      morbidity and mortality, and improved quality of life. Low-molecular-weight 
      heparin (LMWH) is preferred as an effective and safe means for prophylaxis and 
      treatment of VTE. It has largely replaced unfractionated heparin (UFH) and 
      vitamin K antagonists (VKAs). Recently, the development of novel oral 
      anticoagulants (NOACs) that directly inhibit factor Xa or thrombin is a milestone 
      achievement in the prevention and treatment of VTE. This review will focus on the 
      epidemiology and pathophysiology of cancer-associated thrombosis, risk factors, 
      and new predictive biomarkers for VTE as well as discuss novel prevention and 
      management regimens of VTE in cancer according to published guidelines.
FAU - Elyamany, Ghaleb
AU  - Elyamany G
AD  - Department of Hematology, Theodor Bilharz Research Institute, Giza, Egypt. ; 
      Department of Pathology and Blood Bank, Prince Sultan Military Medical City, 
      Riyadh, Saudi Arabia.
FAU - Alzahrani, Ali Mattar
AU  - Alzahrani AM
AD  - Department of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi 
      Arabia.
FAU - Bukhary, Eman
AU  - Bukhary E
AD  - Department of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi 
      Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141204
PL  - United States
TA  - Clin Med Insights Oncol
JT  - Clinical Medicine Insights. Oncology
JID - 101525771
PMC - PMC4259501
OTO - NOTNLM
OT  - cancer
OT  - low-molecular-weight heparin
OT  - management
OT  - thrombosis
EDAT- 2014/12/19 06:00
MHDA- 2014/12/19 06:01
PMCR- 2014/12/04
CRDT- 2014/12/19 06:00
PHST- 2014/07/27 00:00 [received]
PHST- 2014/09/24 00:00 [revised]
PHST- 2014/09/27 00:00 [accepted]
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2014/12/19 06:01 [medline]
PHST- 2014/12/04 00:00 [pmc-release]
AID - cmo-8-2014-129 [pii]
AID - 10.4137/CMO.S18991 [doi]
PST - epublish
SO  - Clin Med Insights Oncol. 2014 Dec 4;8:129-37. doi: 10.4137/CMO.S18991. 
      eCollection 2014.